FTC Distributes Nearly $60 Million From Suboxone Settlements

May 12, 2021

The Federal Trade Commission (FTC) is mailing almost $60 million to 51,875 victims of alleged schemes by Reckitt Benckiser and its former subsidiary Indivior to block generic competitors from producing lower-cost versions of the opioid abuse medication Suboxone (buprenorphine-naloxone).

The FTC reached a $50 million-settlement with Reckitt Benckiser in July 2019 and a $10 million-settlement with Indivior in July 2020.

The Reckitts settlement with the FTC was part of the company’s $1.4 billion settlement with the Department of Justice and multiple states over accusations that the companies falsely promoted Suboxone sublingual film as less susceptible to diversion and abuse than other buprenorphine products.

View today's stories